Sign in
TerminatedNo phase

Investigating Integrative Therapies for Symptom Management in Adults With Acute Leukemia

Key facts

Who runs it
University of Florida
Where
Gainesville, United StatesSee the site
Trial code
Status
Terminated
People taking part
9 people enrolled
Started
9 Aug 2023
Ended
4 Mar 2025
Type of study
Interventional, 2 groupsOne group gets no study treatment, for comparison.
Treatments tested
  • Integrative Therapy
Record updated
7 April 2025
Why it stopped
The PIs left the institution.

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 7 criteriaShow less

Who can take part

  • Admitted to local area Bone Marrow Transplant Unit or Hematology/Oncology during the study period
  • Diagnosed with acute leukemia
  • Receiving high-grade MDS induction chemotherapy
  • Within first 3 days of chemotherapy initiation
  • Age > 18 years
  • Able to speak/read English

Who cannot take part

  • -Altered mental status or diminished level of consciousness as established by daily progress note documented by health care provider, nursing assessment, or at the discretion of the Integrative Therapies practitioner

Where in United States

  • University of FloridaGainesville, United States

About the trial

What the trial wants to find out

This pilot study will use a mixed methods approach to evaluate the feasibility and acceptability of Integrative Therapies, a bedside service offering mindfulness-based interventions (still meditation, meditative movement, relaxation techniques, and massage therapy) as non-pharmacologic treatment for symptom management in newly diagnosed adult Acute Myeloid Leukemia (AML) patients undergoing induction chemotherapy

The 2 groups in the trial

  • Standard of care with integrative therapyTreatment being tested

    For the intervention group, an initial interview will be conducted and the Patient-Reported Outcomes Measurement Information System (PROMIS) and Memorial Symptom Assessment Scale (MSAS) questionnaires will be administered at enrollment. Integrative Therapies will then begin offering two to four sessions weekly. At 7, 14, and 21 days (+-2 days) after the start of induction chemotherapy, the PROMIS and the MSAS questionnaires will be administered again along with an acceptability questionnaire. At 21 (+-2) days after the start of induction chemotherapy, a second interview will be conducted.

    Treatment: Integrative Therapy

  • Standard of care onlyNo study treatment, for comparison

    For the standard care group, an initial interview will be conducted and the PROMIS and MSAS questionnaires will be administered at enrollment. At 7, 14, and 21 days (+-2 days) after the start of induction chemotherapy, the PROMIS and the MSAS questionnaires will be administered again. At 21 days (+-2 days) after the start of induction chemotherapy, a second interview will be conducted.

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Investigating Integrative Therapies for Symptom Management in Adults With Acute Leukemia Undergoing High-grade MDS Induction Chemotherapy
Record updated
7 April 2025